INTRODUCTION
Approximately 20-25% of all people with learning disabilities suffer from epilepsy, a percentage much higher than in the general population. A high seizure frequency, multiple seizure types, frequent complications, such as status epilepticus or injuries, and a high rate of therapy resistance characterise many of the epilepsies in this population. Therefore, the development of each new antiepileptic drug (AED) is a glimmer of hope for these patients.
On the other hand, knowledge about efficacy and tolerability of the new AED in this patient group is limited. Learning disabled patients are often excluded from the regulatory double-blind placebo-controlled trials because of difficulties with consent. The assumption of efficacy of the new AED in this patient group, strictly speaking, is based on the extrapolation of the data of non-disabled patients. Post-marketing studies are needed to evaluate the effects of new drugs in these special populations. There is some literature on the use of lamotrigine (LTG) in learning disabled patients, but only a few articles report on gabapentin (GBP), topiramate (TPM) and the remaining new AEDs.
Levetiracetam (LEV), one of the most recently introduced AED, has been shown to be effective as add-on therapy in treatment-resistant patients with focal (partial) epilepsies. Efficacy proved to be dose-related with daily doses between 1000 and 3000 mg [1] [2] [3] , with no additional effect when doses were further increased up to 4000 mg/day 4, 5 . Only recently, a report on the use of LEV in six developmentally disabled patients was published. This indicated both a good antiepileptic effect and favourable changes in problem behaviours in some of these patients 6 .
The purpose of our study was to examine the efficacy and tolerability of LEV in therapy-resistant epileptic patients with learning disabilities of varying degrees and not excluding those with additional physical handicaps. The ethical and legal restrictions existing in patients, most of whom are not able to give their informed consent, had to be taken into account.
PATIENTS AND METHODS

Inclusion criteria
The Residential Department of the Bethel Epilepsy Centre provides care for approximately 1200 patients with difficult-to-manage therapy-resistant epilepsies, in many cases with accompanying intellectual and/or neurological deficits. Eligibility criteria included: Learning disabled adult and adolescent patients with a confirmed diagnosis of epilepsy, resistant against at least one traditional AED, but in fact the vast majority of all study participants were resistant against several traditional AEDs up to maximum tolerable dosages and in several cases against one or two new AEDs (mostly LTG). The staff physicians of the Bethel Medical Service (mostly neurologists and psychiatrists, all with special experience in the diagnosis and treatment of epilepsy) selected the patients on clinical grounds, preferably patients with frequent and/or disabling seizures. All patients or their legal representatives had given consent to LEV treatment. Forty-eight patients were started on LEV between its introduction in Germany in Autumn 2000 and February 2002. Two patients had to be excluded from the study because seizure documentation was incomplete or unreliable in these cases and so, 46 patients were enrolled in the study.
Methods
The baseline period was defined as the 3 months prior to starting LEV treatment. The first 3 months on LEV were considered to be the titration period, the second 3 (4th-6th) months as treatment or evaluation period. A post-evaluation after 1 year comprises the 10th-12th months on LEV. A second post-evaluation after 2 years is planned, but is not subject of this paper because data are still incomplete.
LEV was added to the pre-existing medication prescribed for each patient. There was no fixed titration scheme. Usually, LEV treatment was started following the manufacturer's recommendations (initial dose 1000 mg/day, divided in two doses), but some physicians preferred to start at lower dosages. Progressive dosage increases followed subject to clinical observations. A maximum dosage of LEV was not pre-set; the aim was to obtain the best possible antiepileptic effects. Clinicians were allowed to adjust the dose of the concomitant AED if it was considered clinically appropriate.
The method of this study is in accordance with the guidelines for observational studies published in Reference 7. According to these guidelines, an observational study is a form of a phase IV post-marketing study which aims to evaluate the benefits and risks of a drug under natural conditions. Therefore, the study should not interfere with routine therapy. For that reason, consent to the new treatment by the patient or his/her legal representative is needed, but not to study participation. The different points of time and the size of data to be raised have to be exactly determined a priori in order to obtain valid data despite the shortcomings of an open study 7 .
The methods and time frames of this study were very similar to other studies on new AED conducted previously in our institution [8] [9] [10] ; it was intended to compare the results to those of the previous studies.
Documentation
Data were extracted retrospectively from the continual seizure records kept on all resident patients and entered into data sheets designed for the purpose of this study. As the institution is specialising in epilepsy and most staff are trained in observing and describing seizures, it is believed that the seizure documentation is as complete and accurate as possible. Besides diagnostic data, medication and seizure frequency per seizure type, possible qualitative changes in seizure severity were noted. Information on seizure severity is based upon staff observations and the patients' own experiences, as summarised by the responsible physician. Criteria applied to judge seizure severity were: seizure duration, time and depth of unconsciousness, and time to complete recovery.
Possible psychotropic effects, as judged clinically by the physicians, and adverse effects (defined as any undesirable effects or patients' complaints when considered probably due to LEV) were recorded, too.
The phenomenological seizure classification currently in use in Bethel is similar to the proposal for a revision of the classification of the International League Against Epilepsy 11 .
Evaluation
As the usual criterion of a 50% seizure reduction is quite arbitrary, an additional evaluation of global clinical efficacy (a 5-point ad hoc-scale: very good, good, modest, none or deteriorated) was made by the physicians. Global clinical efficacy comprises not only numerical effects but also aspects of seizure severity or efficacy against different seizure types. In the same way, overall tolerability was clinically judged (very good, good, moderate, bad) by the treating physicians, based upon staff information and direct patient examination.
A patient was considered a responder, when he or she had at least a >50% seizure reduction and global clinical efficacy was judged very good or good and the patient was still on LEV at the time of evaluation. When clinical efficacy was judged very good or good without a 50% seizure reduction, or when a 50% seizure reduction was present but clinical efficacy was judged less than good (when the two criteria diverged), the responsible physician was contacted by the first author and the case judged individually according to the considered relevance of the LEV effects for the patient's daily activities (details see RESULTS, Table 6 ). Thus, the combination of the two efficacy measures was thought to reflect LEV efficacy as realistic as possible.
RESULTS
The 46 patients' (23 female, 23 male) mean age was 37.0 (range: 13-70) years, their mean duration of Symptomatic/cryptogenic generalised epilepsy (n = 3)
Progressive myoclonus epilepsy (n = 1) 1
GTCS: generalised tonic-clonic seizure. a In the phenomenological seizure classification, any absence-like seizure will be classified as an absence seizure. b Any seizure type was only evaluated when the minimum frequency of that particular seizure type was 2 per month.
epilepsy 30.5 (range: 8-62) years, and their mean duration of residential care in Bethel 17.1 (range: 0.5-52) years.
Diagnoses
See Table 1 for diagnoses of epileptic syndromes. Thirteen patients had mild, 12 had moderate, 11 had severe/profound learning disability. Ten patients had borderline intelligence or neuropsychological deficits like psychomotor slowing or memory disturbance.
Twenty-eight patients had physical handicaps: 5 hemiparesis, 4 tetraparesis, 12 cerebellar syndrome (in 5 cases combined with different forms of paresis), 1 extrapyramidal syndrome, 1 aphasia. In other cases, the exact nature of neurologic impairment was not determined. Eighteen patients were neurologically normal.
Twenty-three patients had a history of psychiatric illness, diagnosed by a staff physician familiar with psychiatric disorders in the learning disabled or, in some cases, by a psychiatrist. The most frequent psychiatric diagnoses were affective disorder (5), psychosis (4), behavioural disorder (4), dementia (4) and personality disorder (3).
Antiepileptic medication
There were only minor changes in concomitant antiepileptic medication (see Table 2 ) between baseline and treatment period: phenobarbitone (PB), oxcarbazepine (OCBZ), topiramate (TPM), carbamazepine (CBZ), methsuximide (MSM), gabapentin (GBP) and sulthiame (ST) were discontinued in one case each. The mean daily dose or serum concentration of valproate (VPA), OCBZ and TPM was somewhat lower 
Effects on seizure frequency
After 6 months, 39/46 (85%) patients were still on LEV. In 7/46 (15%) patients, LEV was discontinued, in all cases because of a lack of efficacy, and additional problems with side effects in 1. 2/46 (4%) patients became completely seizure free, 3/46 (6%) patients experienced a 90% seizure reduction, and another 11/46 (24%) patients a 50% seizure reduction (Table 3 ; efficacy measure 1). In 20/46 (43.5%) patients, global clinical efficacy was judged good or very good by the treating physicians (Table 4 ; efficacy measure 2).
In 12/46 (26%) patients, the two efficacy measures were concurrently positive, they were responders (Table 5) . 22/46 (48%) patients were non-responders following both measures. In 12/46 patients, the two efficacy measures disagreed. As mentioned above, these cases were discussed with the responsible physicians and judged individually, with the emphasis on the impact the new treatment had had on the patients' daily lives. From this group of 12, 7 were considered responders, 5 were considered non-responders. For the individual reasons see Table 6 . Overall, therefore, the number of responders is 19 out of 46 patients, corresponding to a responder rate of 41.3%.
Efficacy in different seizure types and epileptic syndromes
Improvement rates differ considerably between the different seizure types (Fig. 1) . Greatest benefits were seen in patients with isolated auras, myoclonic seizures and generalised tonic-clonic seizures (57.1, 42.9 and 41.2%, respectively) and lowest in tonic seizures and absence seizures (21.1 and 0%, respectively).
The number of responders in the different epileptic syndromes is shown in Fig. 2 . Responder rates in focal/multifocal epilepsy were better than those in generalised epilepsy (Lennox Gastaut Syndrome and symptomatic or cryptogenic generalised epilepsy, taken together), the difference reaching significance (P = 0.028, Fisher's exact test). 
Efficacy in relation to LEV dosage and serum concentration and to co-medication
The mean daily LEV dosage is slightly lower in responders than in non-responders, whereas the mean serum concentrations are very similar (Table 7) . Responders also have slightly higher mean dosages and serum concentrations of PB, LTG and OCBZ, but as the values (given in brackets in Table 7 ) indicate, there is no major difference in these co-medications between the baseline and treatment period.
Eight responders, but only five non-responders, have PB as co-medication (P = 0.104, Fisher's exact test).
All in all, the differences in medication between responders and non-responders were minor.
Qualitative changes in seizure severity
Three patients had milder or shorter seizures, in one of these cases post-ictal recovery was shorter. In another patient, seizures in the treatment period occurred nearly only at night during sleep. In four patients, the propensity to seizure clusters and to seizure-related falls was diminished, but these changes were counted as quantitative improvements (Fig. 1) .
Psychotropic effects
In 10/46 (22%) patients, psychotropic effects were reported, positive changes in 9 cases, unwanted effects in 1 case. There were no psychotropic effects in the remaining patients.
The positive psychotropic effects were mainly an improvement in vigilance, more activity, improved mood, and in two cases more stable mood.
The nine patients with positive psychotropic effects had LEV dosages between 1000 and 4000 mg/ day (mean 2778 mg/day) and serum concentrations between 9 and 67.1 µg/ml (mean 28.8 µg/ml). Six of them were responders, three non-responders.
Tolerability/adverse effects (including unwanted psychotropic effects)
Tolerability, as clinically judged by the treating physicians, was very good (23 cases) or good (13 cases) in most patients. In seven patients, tolerability was moderate, in two cases poor (one case: not evaluable). Twelve patients or their carers reported adverse effects. Somnolence was the most frequent adverse effect (5 cases), followed by mild ataxia (2), vomiting (1) and loss of appetite (1). In only three cases were adverse effects severe: One patient with a pre-existing cerebellar syndrome deteriorated to the point, she was no longer able to a As these values differ slightly between responders and non-responders, the values before LEV treatment are given in brackets for comparison. * P = 0.104.
walk without support (1500 mg/day LEV; 3.5 µg/ml; dosage and serum concentration of concomitant CBZ were unchanged). The second patient suffered from unwanted psychotropic effects (apathy, somnolence, impaired consciousness, and a reduction in drive and activity) on 1000 mg/day LEV (3.9 µg/ml).
Only during the post-evaluation phase did a third patient develop a paranoid-hallucinatory psychosis when LEV dosage was increased from 1000 to 2000 mg/day (serum concentration not determined). This patient had a pre-existing personality disorder but no known history of psychosis. Despite discontinuation of LEV, psychotic symptoms were only incompletely resolved.
An additional case involved an increase in aggression. But this case could possibly be attributed to a reduction of concomitant LTG which had formerly improved aggressive behaviours in this patient.
One patient had tremor, dizziness and gait disturbance (3000 mg/day LEV; 32.4 µg/ml), but this could have been secondary to withdrawal of concomitant primidone.
Post-evaluation after 12 months
After 1 year of LEV treatment, 22/46 (48%) patients were still on LEV, in 17 patients LEV was discontinued (in 7 patients, the duration of LEV treatment was less than 12 months).
Whilst re-evaluating the data at 1 year, two of the former responders had experienced an increase in seizure frequency and no longer fulfilled the criteria for responders, but two of the former non-responders had improved and thus could be considered to be responders.
DISCUSSION
Although the efficacy of LEV is sufficiently proven in general patient populations, there are limited data regarding its use in learning disabled patients. This retrospective observational study was undertaken to assess LEV effects in therapy-resistant resident patients of the Bethel Epilepsy Centre.
The responder rate of 41.3% seems very good in what is a difficult-to-treat patient group. The responder rate is best in the focal epilepsy syndromes, the accepted main indication for LEV, whereas in the generalised epilepsy syndromes efficacy proved to be only 10%, although the number of 10 patients with Lennox Gastaut Syndrome or other symptomatic generalised epilepsy is relatively small. Within seizure syndromes, efficacy was found to be high in focal seizure types (auras, psychomotor seizures), but low in seizure types, such as absence seizures, which are mostly generalised (see footnotes to Table 1 ). As for generalised tonic-clonic and tonic seizures, it is difficult to determine in a retrospective study whether they are focal/focal-onset or primarily generalised. However, further analysis shows 5 out of 10 (50%) patients with generalised tonic-clonic seizures within a focal or multifocal epilepsy, and 5 out of 11 (45.5%) patients with tonic seizures within a focal or multifocal epilepsy had at least a 50% reduction of that particular seizure type. Thus, generalised tonic-clonic seizures as well as tonic seizures in patients with focal epilepsy syndromes respond very well to LEV. Simple focal (partial) seizures other than auras were too rare to be evaluated.
The one patient with a progressive myoclonus epilepsy responded excellently.
To further evaluate treatment outcomes, we used the usual 50% seizure reduction criterion but also included a more individualised global clinical efficacy measure. It could be argued that this gives only a subjective opinion, however, all cases in question have been carefully evaluated and the reasons for decisions are transparent (Table 6 ). Therefore, we feel this is a more adequate way of judging efficacy than only adhering to seizure numbers and reflects clinical practice where decisions are made on more than just seizure reduction. If one prefers to keep to the formal 50% seizure reduction measure, a slightly lower responder rate (16/46 patients or 34.8%) would result (Table 3) .
LEV dosages and serum concentrations were quite similar in responders and non-responders. It was our experience that individual patients could respond to any LEV dose within the usual dosage spectrum of 500-4000 mg/day (serum concentrations between 9 and 53.5 µg/ml). We found no convincing indication for certain co-medications to be more favourable than others.
Qualitative changes in seizure severity occurred only in a small minority of patients.
Nearly one fifth of patients had positive psychotropic effects. Six of these patients also had better seizure control, three did not. It remains difficult to evaluate whether these psychotropic effects are an independent drug effect or secondary to improved seizure control.
Unwanted psychotropic effects occurred very rarely. The one patient who developed a first episode of psychosis on a rapid LEV dosage increase is notable, however, the psychosis did not fully resolve following discontinuation.
Drug tolerability, which in general can be decreased in neurologically impaired patients, proved to be good to very good in the great majority of patients. Most side effects were mild and remitted spontaneously or when the dose was reduced. Strikingly, two of three patients who experienced more severe side effects did so with low LEV doses and serum concentrations. The most frequent side effect was somnolence which occurred with LEV dosages between 2500 and 4000 mg/day. In some cases, somnolence was noticed when LEV dosage was rapidly increased, e.g. by 500 mg b.i.d. In these cases, dosage increments were reduced to 250 mg b.i.d. or 250 once a day.
We have earlier reported on similar studies with LTG, TPM and GBP in the same patient population. In those studies, we found similarly high responder rates of 28.8% for LTG 8 and 37.5% for TPM 10 , but only 10.3% for GBP 9 . Tolerability was also good in LTG and GBP, whereas a considerable number of serious side effects occurred with TPM. With LTG, positive psychotropic effects occurred even more frequently than those observed in LEV, and were apparently independent from the antiepileptic effect. LTG, which at the time was only approved for focal epilepsy (like LEV is at present), proved to be equally effective in generalised epilepsy.
We are aware of the well-known shortcomings of poorly controlled retrospective studies. Nevertheless, we feel the presented data are valid. Major bias by the responsible physicians or staff is improbable because all seizure documentations were part of the regular documentation which is kept on all resident patients independently. Moreover, we attempted to minimise effects of spontaneous fluctuations in seizure frequency by calculating frequency as mean values of 3 months.
CONCLUSIONS
In our experience, LEV is an effective and generally well-tolerated therapy in the difficult-to-treat epilepsies of learning disabled patients. This is especially true for focal epilepsies/focal seizure types. The efficacy in symptomatic/cryptogenic generalised epilepsy remains to be determined; in our study it was minor.
LEV can have positive psychotropic effects like improved vigilance and better or more stable mood in a number of patients. Further study is needed to clarify if this a genuine drug effect or rather a consequence of better seizure control.
As the desired antiepileptic effect can occur at very different doses, it is advisable to titrate stepwise and watch effects. The titration scheme recommended by the manufacturer (steps of 500 mg b.i.d.) may be too rapid for disabled patients, temporary side effects, such as somnolence, may happen less frequently when a slower titration scheme is applied.
